Serina Therapeutics Inc SER 深 沪
交易中 05-19 09:53:55 美东时间
1.54
+0.030
+1.99%
华盛通- 最 高1.57
- 今 开1.57
- 成交量 5915股
- 最 低 1.54
- 昨 收 1.51
- 总市值 2309.62万
- 52周最高 7.92
- 市盈率 静 --
- 换手率 0.04%
- 52周最低 1.22
- 委 比 92.31%
- 总股本 1499.75万
- 历史最高 209.2615
- 量 比 5.36
- 振 幅 1.99%
- 历史最低 1.22
- 每 手 1
- 风险率 1.60%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Serina Therapeutics Says Phase 1b Registrational Clinical Study of SER-252 Underway In Advanced Parkinson's Disease; TFL Data From The SAD Study Arm Targeted For First Half of 2027
SER-252 Phase 1b Registrational Clinical Study: Following dosing of the first patient in February 2026, Serina continues to advance its Phase 1b registrational clinical study of SER-252 in advanced Parkinson's disease.
05-15 05:52
Serina Therapeutics Q1 EPS $(0.58) Misses $(0.44) Estimate
Serina Therapeutics (AMEX:SER) reported quarterly losses of $(0.58) per share which missed the analyst consensus estimate of $(0.44) by 31.82 percent. This is a 18.37 percent decrease over losses of $(0.49) per share
05-15 04:43
Serina Therapeutics presents POZ-based lipid nanoparticle data at LNP formulation summit
Serina Therapeutics presents POZ-based lipid nanoparticle data at LNP formulation summit Serina to present at 5th LNP Formulation & Process Development Summit in Boston, Massachusetts. Event scheduled for April 7, 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using gene
04-07 18:46
Serina Therapeutics Q4 EPS $(0.31) Beats $(0.46) Estimate
Serina Therapeutics (AMEX:SER) reported quarterly losses of $(0.31) per share which beat the analyst consensus estimate of $(0.46) by 32.61 percent. This is a 29.17 percent decrease over losses of $(0.24) per share from
03-26 04:37
Serina Therapeutics (SER) Stock Surges Over 39% After Hours— Here's Why
Serina Therapeutics Inc. surged 39.45% in after-hours trading Wednesday following a $15 million private placement announcement.
03-19 15:11
Serina Therapeutics Announces Up To $30M In Private Placement To Support Registrational Trial Of SER-252 Parkinson's Treatment
- First tranche of $15 million expected to close on March 20, 2026; second tranche of up to $15 million available, for up to $30 million in total proceeds from the sale of common stock and pre-funded warrants priced at
03-19 04:13
Serina Therapeutics enrolls first patient in Phase 1b registrational trial of SER-252 for advanced Parkinson’s disease
Serina Therapeutics enrolls first patient in Phase 1b registrational trial of SER-252 for advanced Parkinson’s disease Serina Therapeutics said it has enrolled the first patient in a global Phase 1b registrational trial of SER-252 for advanced Parkinson’s disease. The study will evaluate safety, tol
02-19 19:00
Why DarkIris Shares Are Trading Higher By Over 100%; Here Are 20 Stocks Moving Premarket
Shares of DarkIris Inc (NASDAQ:DKI) rose sharply in pre-market trading after th...
02-02 18:17
Market-Moving News for January 29th
META: 10% | Meta Platforms shares are trading higher after the company reported better-than-expected Q4 financial results and issued Q1 sales guidance above estimates. TSLA: 4% | Tesla Q4
01-29 20:22
